Sanofi Still Bets On Multiple Sclerosis Med Tolebrutinib Despite The Investigational Drug Fell Short In 2 Of 3 Phase 3 Trials. Story by Vandana Singh • 1mo. S unday, ...

Sanofi said an oral treatment for multiple sclerosis, tolebrutinib, met its key goal in a Phase 3 study, potentially clearing the way for regulatory approval, although in two other studies ...

Sanofi’s experimental drug for a form of multiple sclerosis delayed the progression of disability by nearly a third, providing hope for patients for whom there’s currently no treatment.

Sanofi‘s most advanced multiple sclerosis drug candidate failed to achieve the main goal of two late-stage trials to treat relapsing forms of the disease.However, the drug was able to succeed in ...

Sanofi has stopped a phase 2 trial of Denali Therapeutics-partnered oditrasertib in multiple sclerosis. The French drugmaker tore the RIPK1 inhibitor trial from its list of active studies after it ...

Sanofi Multiple Sclerosis Drug Delays Disability Progression in Trial — Update Provided by Dow Jones Sep 2, 2024, 8:29:00 AM. By David Sachs and Adria Calatayud .

Sanofi (NASDAQ:SNY) said on Tuesday that the US FDA has granted priority review for the regulatory submission of tolebrutinib for the treatment of multiple sclerosis. According to the French ...

Denali Therapeutics said on Thursday its partner Sanofi has discontinued a mid-stage study testing their experimental drug to treat multiple sclerosis as it failed to meet the main and secondary ...

(Reuters) -Sanofi's most advanced multiple sclerosis drug candidate has missed the main goal of two late-stage trials to treat relapsing forms of the disease, but in a positive surprise succeeded ...

Sanofi Still Bets On Multiple Sclerosis Med Tolebrutinib Despite The Investigational Drug Fell Short In 2 Of 3 Phase 3 Trials. Sunday, Sanofi SA’s (NASDAQ:SNY) data from the HERCULES phase 3 ...

A Sanofi experimental drug for multiple sclerosis delayed disability progression in a late-stage trial, but failed to reduce episodes of new or worsening symptoms compared to an existing treatment ...